Email updates

Keep up to date with the latest news and content from BMC Medicine and BioMed Central.

Journal App

google play app store
Open Access Research article

Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review

Frank Kunath12*, Bastian Keck2, Gerd Antes1, Bernd Wullich2 and Joerg J Meerpohl13

Author Affiliations

1 German Cochrane Center, Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg, Berliner Allee 29, 79110 Freiburg/Br., Germany

2 Department of Urology, University Clinic Erlangen, Krankenhausstr. 12, 91054 Erlangen, Germany

3 Pediatric Hematology and Oncology, Center for Pediatrics and Adolescent Medicine, University Medical

For all author emails, please log on.

BMC Medicine 2012, 10:96  doi:10.1186/1741-7015-10-96

Published: 28 August 2012

Additional files

Additional file 1:

Table S1: Search strategy Table S2: Adverse events: Tamoxifen (10 or 20 mg daily) versus no additional therapy or placebo Table S3: Adverse events: Tamoxifen (20 mg daily) versus anastrozole (1 mg daily) Table S4: Adverse events: Tamoxifen (10 mg daily) versus radiotherapy (single fraction of 12 Gy).

Format: PDF Size: 113KB Download file

This file can be viewed with: Adobe Acrobat Reader

Open Data